On May 1, 2024 RS Oncology, a clinical-stage biopharmaceutical company focused on developing novel treatments for aggressive and rare cancers, reported that it will present the complete Phase 1 dose escalation data as an oral presentation at the world’s largest oncology meeting, the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, RS Oncology, MAY 1, 2024, View Source [SID1234642525]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The MITOPE phase 1 multicenter study, (clinical trials.gov #NCT05278975) investigating the safety and tolerability of RSO-021, is a first-in-human trial. RSO-021 is a first-in-class therapy for treatment of mesothelioma and solid tumors in patients with malignant pleural effusion. Professor Dean Fennell from Leicester Hospitals Trust in the UK will present the complete dose escalation data as part of a rapid oral session and answer questions during a moderated panel discussion.
Aggressive cancers present tremendous challenges in treatment and management, primarily due to rapid growth and spread to other parts of the body. Malignant pleural effusion (MPE) develops as a direct extension of cancer into the pleural space and is associated with shorter life expectancies. Currently, the phase 2 expansion portion of MITOPE is underway in the UK, exploring RSO-021 as both a single agent and in combination therapy to treat stage IV metastatic cancers with MPE, including mesothelioma, lung, breast and ovarian cancers. Other causes of MPE include cancer that has spread from the stomach, kidney, ovaries, and colon. Dr. Sean Dulloo from University of Leicester will present an update of the MITOPE Phase 2 trial as a trial-in-progress poster presentation.
The data is embargoed until published by ASCO (Free ASCO Whitepaper) 5:00 PM (EDT) on Thursday, May 23, 2024.
Details of the Presentations
Rapid Oral Abstract
Title: First-in-human phase 1 clinical trial of RSO-021, a first-in-class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).
Presenter: Dean Fennell
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Day/Time: Monday June 3, 9:06 am (session from 8:00-9:30 am)
Abstract #3019
Poster Presentation
Title: Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.
Presenter: Sean Dulloo
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Day/Time: Monday, June 3, from 1:30 – 4:30 PM CDT
Abstract: #TPS8124
Poster Bd: #381b